Diclofenac 3% Gel, Diclofenac 1.5% and 2% Topical Solution
|
|
- Patrick Marsh
- 5 years ago
- Views:
Transcription
1 Texas Prior Authorization Program Clinical Criteria Drug/Drug Class, Diclofenac 1.5% and 2% Topical Solution This criteria was recommended for review by an MCO to ensure appropriate and safe utilization Clinical Information Included in this Document Diclofenac 3% Topical Gel Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical criteria rules Logic diagram: a visual depiction of the clinical criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable References: clinical publications and sources relevant to this clinical criteria te: Click the hyperlink to navigate directly to that section August 3, 2017 Copyright Health Information Designs, LLC 1
2 Diclofenac 1.5% and 2% Topical Solution Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical criteria rules Logic diagram: a visual depiction of the clinical criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable References: clinical publications and sources relevant to this clinical criteria te: Click the hyperlink to navigate directly to that section Revision tes Updated with DUR Board Recommendations 1. Changed all lookback periods to 730 days, page 4 2. Added question 3, history of GI bleed, page 4 3. Updated logic diagram, page 5 4. Added table 3, page Added question 3, history of GI bleed, page Updated logic diagram, page Added table 3, page 12 August 3, 2017 Copyright Health Information Designs, LLC 2
3 Drugs Requiring Prior Authorization Drugs Requiring Prior Authorization Label Name GCN DICLOFENAC SODIUM 3% GEL SOLARAZE 3% GEL August 3, 2017 Copyright Health Information Designs, LLC 3
4 Clinical Criteria Logic 1. Is the client greater than or equal to ( ) 18 years of age? [ ] (Go to #2) [ ] (Deny) 2. Does the client have a diagnosis of actinic keratosis in the last 730 days? [ ] (Go to #3) [ ] (Deny) 3. Does the client have a history of a GI bleed in the last 730 days? [ ] (Deny) [ ] (Go to #4) 4. Does the client have a claim for topical fluorouracil, imiquimod cream or ingenol mebutate gel in the last 730 days? [ ] (Approve 90 days) [ ] (Go to #5) 5. Has the client tried laser surgery, electrosurgery, cryosurgery, chemosurgery or surgical curettement in the last 730 days? [ ] (Approve 90 days) [ ] (Deny) August 3, 2017 Copyright Health Information Designs, LLC 4
5 Clinical Criteria Logic Diagram Step 1 Is the client 18 years of age? Deny Request Step 2 Does the client have a diagnosis of actinic keratosis in the last 730 days? Deny Request Step 3 Does the client have a diagnosis of a GI bleed in the last 730 days? Deny Request Step 4 Step 5 Does the client have a claim for topical fluorouracil, imiquimod cream or ingenol mebutate gel in the last 730 days? Has the client tried laser surgery, electrosurgery, cryosurgery, chemosurgery or surgical curettement in the last 730 days? Deny Request Approve Request (90 days) Approve Request (90 days) August 3, 2017 Copyright Health Information Designs, LLC 5
6 Diclofenac 3% Topical Gel Clinical Criteria Supporting Tables ICD-10 code L570 Step 2 (diagnosis of actinic keratosis) Required diagnosis: 1 Look back timeframe: 730 days Description ACTINIC KERATOSIS ICD-10 code K250 K251 K252 K253 K254 K255 K256 K257 K259 K260 K261 K262 K263 K264 K265 K266 K267 K269 Description Step 3 (diagnosis of GI bleed) Required diagnosis: 1 Look back timeframe: 730 days ACUTE GASTRIC ULCER WITH HEMORRHAGE ACUTE GASTRIC ULCER WITH PERFORATION ACUTE GASTRIC ULCER WITH BOTH HEMORRHAGE AND PERFORATION ACUTE GASTRIC ULCER WITHOUT HEMORRHAGE OR PERFORATION CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH PERFORATION CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH BOTH HEMORRHAGE AND PERFORATION CHRONIC GASTRIC ULCER WITHOUT HEMORRHAGE OR PERFORATION GASTRIC ULCER, UNSPECIFIED AS ACUTE OR CHRONIC, WITHOUT HEMORRHAGE OR PERFORATION ACUTE DUODENAL ULCER WITH HEMORRHAGE ACUTE DUODENAL ULCER WITH PERFORATION ACUTE DUODENAL ULCER WITH BOTH HEMORRHAGE AND PERFORATION ACUTE DUODENAL ULCER WITHOUT HEMORRHAGE OR PERFORATION CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH PERFORATION CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH BOTH HEMORRHAGE AND PERFORATION CHRONIC DUODENAL ULCER WITHOUT HEMORRHAGE OR PERFORATION DUODENAL ULCER, UNSPECIFIED AS ACUTE OR CHRONIC, WITHOUT HEMORRHAGE OR PERFORATION August 3, 2017 Copyright Health Information Designs, LLC 6
7 Diclofenac 3% Topical Gel K270 K271 K272 K273 K274 K275 K276 K277 K279 Step 3 (diagnosis of GI bleed) Required diagnosis: 1 Look back timeframe: 730 days ACUTE PEPTIC ULCER, SITE UNSPECIFIED, WITH HEMORRHAGE ACUTE PEPTIC ULCER, SITE UNSPECIFIED, WITH PERFORATION ACUTE PEPTIC ULCER, SITE UNSPECIFIED, WITH BOTH HEMORRHAGE AND PERFORATION ACUTE PEPTIC ULCER, SITE UNSPECIFIED, WITHOUT HEMORRHAGE OR PERFORATION CHRONIC OR UNSPECIFIED PEPTIC ULCER, SITE UNSPECIFIED, WITH HEMORRHAGE CHRONIC OR UNSPECIFIED PEPTIC ULCER, SITE UNSPECIFIED, WITH PERFORATION CHRONIC OR UNSPECIFIED PEPTIC ULCER, SITE UNSPECIFIED, WITH BOTH HEMORRHAGE AND PERFORATION CHRONIC PEPTIC ULCER, SITE UNSPECIFIED, WITHOUT HEMORRHAGE OR PERFORATION PEPTIC ULCER, SITE UNSPECIFIED, UNSPECIFIED AS ACUTE OR CHRONIC, WITHOUT HEMORRHAGE OR PERFORATION Step 4 (claim for a topical fluorouracil, imiquimod cream or ingenol mebutate gel) Required claims: 1 Look back timeframe: 730 days Label Name GCN EFUDEX 5% CREAM FLUOROURACIL 0.5% CREAM FLUOROURACIL 2% TOPICAL SOLN FLUOROURACIL 5% CREAM FLUOROURACIL 5% TOP SOLUTION IMIQUIMOD 5% CREAM PACKET PICATO 0.015% GEL PICATO 0.05% GEL TOLAK 4% CREAM ZYCLARA 3.75% CREAM August 3, 2017 Copyright Health Information Designs, LLC 7
8 Diclofenac 3% Topical Gel CPT Code Step 5 (CPT code for laser surgery, electrosurgery, cryosurgery, chemosurgery or surgical curettement) Description Required CPT code: 1 Look back timeframe: 730 days DESTRUCTION (E.G., LASER SURGERY, ELECTROSURGERY, CRYOSURGERY, CHEMOSURGERY, SURGICAL CURETTEMENT), PREMALIGNANT LESIONS (E.G., ACTINIC KERATOSES); FIRST LESION DESTRUCTION (E.G., LASER SURGERY, ELECTROSURGERY, CRYOSURGERY, CHEMOSURGERY, SURGICAL CURETTEMENT), PREMALIGNANT LESIONS (E.G., ACTINIC KERATOSES); 2 THROUGH 14 LESIONS DESTRUCTION (E.G., LASER SURGERY, ELECTROSURGERY, CRYOSURGERY, CHEMOSURGERY, SURGICAL CURETTEMENT), PREMALIGNANT LESIONS (E.G., ACTINIC KERATOSES); 15 OR MORE LESIONS August 3, 2017 Copyright Health Information Designs, LLC 8
9 Drugs Requiring Prior Authorization Drugs Requiring Prior Authorization Label Name GCN DICLOFENAC 1.5% TOPICAL SOLUTION PENNSAID 2% PUMP August 3, 2017 Copyright Health Information Designs, LLC 9
10 Clinical Criteria Logic 1. Is the client greater than or equal to ( ) 18 years of age? [ ] (Go to #2) [ ] (Deny) 2. Does the client have a diagnosis of osteoarthritis of the knee in the last 730 days? [ ] (Go to #3) [ ] (Deny) 3. Does the client have a history of a GI bleed in the last 730 days? [ ] (Deny) [ ] (Approve 90 days) August 3, 2017 Copyright Health Information Designs, LLC 10
11 Clinical Criteria Logic Diagram Step 1 Is the client 18 years of age? Deny Request Step 2 Does the client have a diagnosis of osteoarthritis of the knee in the last 730 days? Deny Request Step 3 Does the client have a diagnosis of GI bleed in the last 730 days? Deny Request Approve Request (90 days) August 3, 2017 Copyright Health Information Designs, LLC 11
12 / Clinical Criteria Supporting Tables ICD-10 code M170 M1710 M1711 M1712 M172 M1730 M1731 M1732 M174 M175 M179 Step 2 (diagnosis of osteoarthritis of the knee) Description Required diagnosis: 1 Look back timeframe: 730 days BILATERAL PRIMARY OSTEOARTHRITIS OF KNEE UNILATERAL PRIMARY OSTEOARTHRITIS, UNSPECIFIED KNEE UNILATERAL PRIMARY OSTEOARTHRITIS, RIGHT KNEE UNILATERAL PRIMARY OSTEOARTHRITIS, LEFT KNEE BILATERAL POST-TRAUMATIC OSTEOARTHRITIS OF KNEE UNILATERAL POST-TRAUMATIC OSTEOARTHRITIS, UNSPECIFIED KNEE UNILATERAL POST-TRAUMATIC OSTEOARTHRITIS, RIGHT KNEE UNILATERAL POST-TRAUMATIC OSTEOARTHRITIS, LEFT KNEE OTHER BILATERAL SECONDARY OSTEOARTHRITIS OF KNEE OTHER UNILATERAL SECONDARY OSTEOARTHRITIS OF KNEE OSTEOARTHRITIS OF KNEE, UNSPECIFIED Step 3 (diagnosis of GI bleed) Required diagnosis: 1 Look back timeframe: 730 days For the list of diagnoses that pertain to this step, see the GI Bleed Diagnoses table in the previous Supporting Tables section. te: Click the hyperlink to navigate directly to the table. August 3, 2017 Copyright Health Information Designs, LLC 12
13 / Clinical Criteria References ICD-9-CM Diagnosis Codes Available at Accessed on July 28, ICD-10-CM Diagnosis Codes Available at Accessed on July 28, Clinical Pharmacology [online database]. Tampa, FL: Elsevier/Gold Standard, Inc.; Available at Accessed on July 28, Micromedex [online database] Available at Accessed on July 28, Solaraze Prescribing Information. Melville, NY. PharmaDerm. May Pennsaid Prescribing Information. Lake Forest, IL. Horizon Pharma USA Inc. May August 3, 2017 Copyright Health Information Designs, LLC 13
14 / Publication History The Publication History records the publication iterations and revisions to this document. tes for the most current revision are also provided in the Revision tes on the first page of this document. Publication Date tes 07/28/2017 Initial publication and presentation to the DUR Board 08/03/2017 Updated with DUR Board Recommendations Changed all lookback periods to 730 days, page 4 Added question 3, history of GI bleed, page 4 Updated logic diagram, page 5 Added table 3, page 6-7 Added question 3, history of GI bleed, page 10 Updated logic diagram, page 11 Added table 3, page 12 August 3, 2017 Copyright Health Information Designs, LLC 14
Texas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationSitagliptin (Januvia)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document 25mg Drugs requiring prior authorization: the list of drugs requiring prior
More informationTexas Prior Authorization Program Clinical Criteria. This criteria was recommended for review by an MCO to ensure appropriate and safe utilization.
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class This criteria was recommended for review by an MCO to ensure appropriate and safe utilization. Clinical Information Included in this
More informationAmitiza (Lubiprostone)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationMethylnaltrexone Bromide (Relistor)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationDipeptidyl Peptidase-4 (DPP-4) Inhibitors
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document DPP-4 Inhibitor Criteria A: Alogliptin 6.25mg, Januvia 25mg, Nesina 6.25mg, Onglyza
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Aldara 5% Cream Drugs requiring prior authorization: the list of drugs requiring
More informationSodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Combination Agents
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Combination Agents This criteria was recommended for review by an MCO to ensure appropriate
More informationTexas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Aldurazyme Adagen Carbaglu Ceprotin Elaprase Fabrazyme Lumizyme Naglazyme Orfandin Ravicti Vimizim Note: Click the hyperlink to navigate
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Xifaxan 200mg Drugs requiring prior authorization: the list of drugs requiring
More informationTexas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Information Included in this Document Xifaxan 200mg Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationLidoderm (Lidocaine) Patch
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Provigil (Modafinil) Drugs requiring prior authorization: the list of drugs
More informationTexas Prior Authorization Program Clinical Criteria. Allergen Extracts
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Information Included in this Document Oralair (Mixed Grass Pollens Allergen Extract)) Drugs requiring prior authorization: the
More informationFentanyl Agents Clinical Edit Criteria
Fentanyl Agents Clinical Edit Criteria Drug/Drug Class: Fentanyl Agents Superior HealthPlan follows the guidance of the Texas Vendor Drug Program (VDP) for all clinical edit criteria. Superior has adjusted
More informationTexas Prior Authorization Program Clinical Edit Criteria. H.P. Acthar
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationHypoglycemics, Lantus Insulin
Texas Prior Authorization Program PDL Edit Criteria Drug/Drug Class Hypoglycemics, Lantus Insulin Information Included in this Document Hypoglycemics, Lantus Insulin Drugs requiring prior authorization:
More informationKeratolytics and Other Topical Dermatological Agents
DRUG POLICY Keratolytics and Other Topical Dermatological Agents BENEFIT APPLICATION Benefit determinations are based on the applicable contract language in effect at the time the services were rendered.
More informationVictoza (Liraglutide) Solution for Injection
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationTopical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary
Topical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-8 Topical Diclofenac Gel Indication
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Thiazolidinediones Clinical Edit Information Included in this Document Thiazolidinediones Drugs requiring prior authorization: the
More informationAgents for the Treatment of Hepatitis C
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationPrior Authorization Neurontin (gabapentin) 2016
Drugs Requiring Prior Authorization Label Name GCN GABAPENTIN 100 MG CAPSULE 00780 GABAPENTIN 300 MG CAPSULE 00781 GABAPENTIN 400 MG CAPSULE 00782 GABAPENTIN 250 MG/5 ML SOLN 13235 GABAPENTIN 600 MG TABLET
More informationInjectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Injectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH) Clinical Edit Information Included in this Document
More informationFlexeril/Amrix (Cyclobenzaprine) Clinical Edit Criteria
Flexeril/Amrix (Cyclobenzaprine) Clinical Edit Criteria Drug/Drug Class: Flexeril/Amrix (Cyclobenzaprine) Superior HealthPlan follows the guidance of the Texas Vendor Drug Program (VDP) for all clinical
More informationTexas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Ketorolac Clinical Criteria Information Included in this Document Ketorolac Oral Drugs requiring prior authorization: the list of drugs
More informationAgents for Cystic Fibrosis
Texas Prior Authorization Program Clinical Edit Criteria Clinical Edit Information Included in this Document Kalydeco (Ivacaftor) Drugs requiring prior authorization: the list of drugs requiring prior
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class COX-2 Inhibitors Clinical Edit Information Included in this Document COX-2 Inhibitors Celebrex Drugs requiring prior authorization:
More informationPrior Authorization Flexeril/Amrix (cyclobenzaprine) 2017
Drugs Requiring Prior Authorization Label Name GCN AMRIX ER 15 MG CAPSULE 97959 AMRIX ER 30 MG CAPSULE 97960 CYCLOBENZAPRINE 10 MG TABLET 18020 CYCLOBENZAPRINE 5 MG TABLET 12805 CYCLOBENZAPRINE 7.5 MG
More informationFlexeril/Amrix (Cyclobenzaprine)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Duexis) Reference Number: CP.PMN.120 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document - Oral Drugs requiring prior authorization: the list of drugs requiring prior
More informationByetta (Exenatide Injection)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationPICATO (ingenol mebutate) gel
PICATO (ingenol mebutate) gel Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationCough/Cold Medications
Texas Prior Authorization Program Clinical Edit Criteria Cough/Cold Medications NOTE: Claims for cough and cold products containing acetaminophen, ibuprofen, or hydrocodone are not covered by Texas Medicaid
More informationAldara. Aldara (imiquimod) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.19 Subject: Aldara Page: 1 of 5 Last Review Date: March 17, 2017 Aldara Description Aldara (imiquimod)
More informationGlucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria
Glucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria Drug/Drug Class: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Superior HealthPlan follows the guidance of the Texas Vendor Drug
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Oral Drugs requiring prior authorization: the list of drugs requiring prior
More informationDrugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria
Drug/Drug Class Antipsychotics Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior
More informationDiagnosis and Management of Actinic Keratosis (AKs)
Diagnosis and Management of Actinic Keratosis (AKs) Andrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationALPHA BLOCKERS. Products Affected. Details. Step 2: RAPAFLO 4 MG CAPSULE. Step 1: alfuzosin extended release tablet doxazosin tablet
ALPHA BLOCKERS RAPAFLO 4 MG CAPSULE RAPAFLO 8 MG CAPSULE drug may be given. alfuzosin extended release tablet doxazosin tablet tamsulosin capsule terazosin capsule 1 ANTIDEPRESSANTS - SNRI FETZIMA 10 MG
More informationCystic Fibrosis Agents
Texas Prior Authorization Program Clinical Criteria Clinical Information Included in this Document Kalydeco (Ivacaftor) Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, BlueCross BlueShield of WNY requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition.
More informationCystic Fibrosis Agents
Texas Prior Authorization Program Clinical Criteria Clinical Information Included in this Document Kalydeco (Ivacaftor) Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, BlueShield of Northeastern New York requires you to first try certain drugs to treat your medical condition before we will cover another drug for that
More informationClinical Policy: Benign Skin Lesion Removal Reference Number: CP.MP.HN150
Clinical Policy: Reference Number: CP.MP.HN150 Effective Date: 6/04 Last Review Date: 8/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, BlueShield of Northeastern New York requires you to first try certain drugs to treat your medical condition before we will cover another drug for that
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationContents ALPHA BLOCKERS... 3 COLCRYS-PST... 4 DPP-4 INHIBITORS-PST... 5 HIGH RISK MEDICATIONS - SEDATIVE HYPNOTICS... 6
CHRISTUS Health Plan Generations (HMO) 2017 Step Therapy Criteria H1189_PC57 Accepted 11/17/2016 1 Contents ALPHA BLOCKERS... 3 COLCRYS-PST... 4 DPP-4 INHIBITORS-PST... 5 HIGH RISK MEDICATIONS - SEDATIVE
More information2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements
2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements AlohaCare requires you to first try one drug to treat your medical condition before we will cover another drug for
More informationICD 10 Codes. L82.1 Seborrheic Keratosis L82.0 Irritated Seborrheic Keratosis
Leon H. Kircik M.D. Clinical Associate Professor of Dermatology Indiana University School of Medicine Mount Sinai Medical Center, New York, NY Physicians Skin Care, PLLC Louisville, KY 1 ICD 10 Codes L82.1
More informationSkin lesions The Good and the Bad. Dr Virginia Hubbard Ipswich Hospital NHS Trust Barts and the London School of Medicine and Dentistry
Skin lesions The Good and the Bad Dr Virginia Hubbard Ipswich Hospital NHS Trust Barts and the London School of Medicine and Dentistry Case 1 32 year old woman Australian Lesion on back New hair growing
More informationXyrem (Sodium Oxybate)
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationName of Policy: Pulsed Dye Laser Treatment of Recalcitrant Verrucae
Name of Policy: Pulsed Dye Laser Treatment of Recalcitrant Verrucae Policy #: 187 Latest Review Date: July 2010 Category: Surgery Policy Grade: Active Policy but no longer scheduled for regular literature
More informationIntegumentary system pertains to the skin, subcutaneous tissue and areolar tissue.
TRICARE/CHAMPUS POLICY MANUAL 6010.47-M DEC 1998 Surgery And Related Services CHAPTER 3 SECTION 2.1 Issue Date: August 26, 1985 Authority: 32 CFR 199.4(c)(2) and (c)(3) I. PROCEDURE CODE RANGE 10040-19499
More informationField vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM
Dilemmas and Challenges in Skin Cancer Therapies and Management Field vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM Roger I. Ceilley, M.D. Clinical Professor of Dermatology The University of Iowa
More information2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements
2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements AlohaCare requires you to first try one drug to treat your medical condition before we will cover another drug for
More information2017 Step Therapy (ST) Criteria
2017 Step Therapy (ST) Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a drug that
More informationDrug Regimen Optimization
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Excluding Valsartan / Ramipril Prior authorization criteria logic: a description
More information2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements
2018 AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Step Therapy Requirements AlohaCare requires you to first try one drug to treat your medical condition before we will cover another drug for
More informationRichard Turner Consultant Dermatologist
Old Problems & New Treatments Photo Album by Administrator Richard Turner Consultant Dermatologist Plan for tonight? Refresher on SCC and solar keratosis How to distinguish the two Classic therapy than
More informationALPHA BLOCKERS. Products Affected Step 1: Details. Step 2: Rapaflo 4 mg capsule Rapaflo 8 mg capsule
CHRISTUS Health Plan Generations (HMO) CHRISTUS Health Plan Generations Plus (HMO) 2018 Premier Performance Standard Step Therapy PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT SOME OF THE DRUGS
More informationDrug Regimen Optimization
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Excluding Valsartan / Ramipril Prior authorization criteria logic: a description
More information2018 Step Therapy (ST) Criteria
2018 Step Therapy (ST) Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a drug that
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Ingenol mebutate (Picato ) 150 micrograms/g gel and 500 micrograms/g gel. Reference number: 1392 FULL SUBMISSION
AWMSG SECRETARIAT ASSESSMENT REPORT Ingenol mebutate (Picato ) 150 micrograms/g gel and 500 micrograms/g gel Reference number: 1392 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics
More informationTopical Products with Quantity Limits
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Page: 1 of 8 Last Review Date: November 30, 2018 Description Apexicon E Topical Cream 0.05% (diflorasone
More informationCoding Companion for Orthopaedics Lower: Hips & Below. A comprehensive illustrated guide to coding and reimbursement
Coding Companion for Orthopaedics Lower: Hips & Below comprehensive illustrated guide to coding and reimbursement 2015 Contents Getting Started with Coding Companion...i Skin...1 Nails...12 Repair...21
More informationScottish Medicines Consortium
Scottish Medicines Consortium imiquimod 5% cream (Aldara) No. (385/07) Meda Pharmaceuticals Ltd 04 April 2008 The Scottish Medicines Consortium has completed its assessment of the above product and advises
More informationTopical Immunomodulators
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Topical Immunomodulators Clinical Criteria Information Included in this Document Topical Immunomodulators Elidel and Protopic 0.03% Drugs
More informationTOPICAL TREATMENT OF ACTINIC KERATOSIS
TOPICAL TREATMENT OF ACTINIC KERATOSIS Gary Goldenberg, MD Goldenberg Dermatology, PC Assistant Clinical Professor of Dermatology The Icahn School of Medicine at Mount Sinai Hospital Conflicts of Interest
More informationLumps and Bumps: An Organized Approach to Diagnosis and Management. Disclosure. Introduction. References. Structure of Skin.
Lumps and Bumps: An Organized Approach to Diagnosis and Management Nothing to disclose Disclosure Tammy Pifer Than, MS, OD, FAAO Carl Vinson VAMC tammythan@bellsouth.net References Fitzpatrick's Color
More informationTreatment or Removal of Benign Skin Lesions
Treatment or Removal of Benign Skin Lesions Date of Origin: 10/26/2016 Last Review Date: 12/15/2017 Effective Date: 10/25/2017 Dates Reviewed: 10/2016, 10/2017, 12/15/2017 Developed By: Medical Necessity
More informationInsert to September 2018 A PRACTICAL APPROACH: Field Treatment of AKs with PDT SUPPORTED BY BIOFRONTERA
Insert to September 2018 A PRACTICAL APPROACH: Field Treatment of AKs with PDT SUPPORTED BY BIOFRONTERA A Practical Approach: Field Treatment of AKs with PDT Why it s essential to treat visible and invisible
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. 5-aminolaevulinic acid (Ameluz ) 78 mg/g gel. Reference number: 1074 FULL SUBMISSION
AWMSG SECRETARIAT ASSESSMENT REPORT 5-aminolaevulinic acid (Ameluz ) 78 mg/g gel Reference number: 1074 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics and Toxicology Centre
More informationPolicy Evaluation: Proton Pump Inhibitors (PPIs)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDeveloping the next generation of dermatology products to treat serious skin diseases
Developing the next generation of dermatology products to treat serious skin diseases Tom Wiggans Chairman and Chief Executive Officer www.peplin.com Forward Looking Statements This presentation contains
More informationAcetaminophen/Aspirin/Ibuprofen Containing Immediate Release Opioid Analgesics: Quantity Limit Policy
DRUG POLICY Acetaminophen/Aspirin/Ibuprofen Containing Immediate Release Opioid Analgesics: Quantity Limit Policy BENEFIT APPLICATION Benefit determinations are based on the applicable contract language
More informationLocal Coverage Determination (LCD) for Actinic Keratosis (L28232)
Page 1 of 12 Search Home Medicare Medicaid CHIP About CMS Regulations & Guidance Research, Statistics, Data & Systems Outreach & Education People with Medicare & Medicaid Questions Careers Newsroom Contact
More informationNew Medicines Committee Briefing May 2015
New Medicines Committee Briefing May 2015 Picato (ingenol mebutate) 150 or 500 mcg/g gel for treatment of nonhyperkeratotic, non-hypertrophic actinic keratosis (AK) in adults. Picato is to be reviewed
More informationTexas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationCOLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet
COLCRYS-PST Mitigare 0.6 mg capsule Colcrys 0.6 mg tablet Criteria If the patient has tried one Step 1 product, authorization for a Step 2 product may be given. Exceptions can be made for a step 2 drug
More informationIcd 9 code for bilateral knee pain for 2017
P ford residence southampton, ny Icd 9 code for bilateral knee pain for 2017 1-10-2017 Pain in right knee. 2016 2017 2018 Billable/Specific Code. M25.561 is a billable/specific ICD -10-CM indicate a diagnosis
More informationVesicular Monoamine Transporter 2 (VMAT2) Inhibitors
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors Clinical Edit Information Included in this Document Austedo (Deutetrabenazine) /
More informationOpinion 26 June 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 26 June 2013 PICATO 150 µg/g, gel 3 tubes of 0.47 g (CIP: 34009 268 528-4 9) PICATO 500 µg/g, gel 2 tubes of 0.47
More informationfluorouracil 0.5% / salicylic acid 10% cutaneous solution (Actikerall ) SMC No. (728/11) Almirall S.A.
fluorouracil 0.5% / salicylic acid 10% cutaneous solution (Actikerall ) SMC No. (728/11) Almirall S.A. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationDrugs That Require Step Therapy (ST) Step Therapy Medications
Drugs That Require Step Therapy (ST) In some cases, BlueShield of Northeastern New York requires you to first try certain drugs to treat your medical condition before we will cover another drug for that
More informationSample page. Plastics/Dermatology A comprehensive illustrated guide to coding and reimbursement CODING COMPANION
Plastics/Dermatology A comprehensive illustrated guide to coding and reimbursement 2020 CODING COANION Power up your coding optum360coding.com Contents Getting Started with Coding Companion...i Resequencing
More information2018 WPS MedicareRx Plan (PDP) Step Therapy
2018 WPS MedicareRx Plan (PDP) Step Therapy In some cases, the WPS MedicareRx Plan (PDP) requires you to first try certain drugs to treat your medical condition before we will cover another drug for that
More informationCOLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet
COLCRYS-PST Mitigare 0.6 mg capsule Colcrys 0.6 mg tablet Criteria If the patient has tried one Step 1 product, authorization for a Step 2 product may be given. Exceptions can be made for a step 2 drug
More informationGlenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine
Glenn D. Goldman, MD University of Vermont Medical Center University of Vermont College of Medicine Recognize and identify the main types of skin cancer and their precursors Identify and understand new
More informationIngenol Mebutate: A Succinct Review of a Succinct Therapy
Dermatol Ther (Heidelb) (2014) 4:157 164 DOI 10.1007/s13555-014-0061-2 REVIEW Ingenol Mebutate: A Succinct Review of a Succinct Therapy David Rhys Alchin To view enhanced content go to www.dermtherapy-open.com
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationScottish Medicines Consortium
Scottish Medicines Consortium ketoprofen/, 100mg/20mg; 200mg/20mg modified release capsules (Axorid ) No. (606/10) Meda Pharmaceuticals 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationFinancial Implications of ICD 10 in 2016
Financial Implications of ICD 10 in 2016 Matthew Menendez Takeaways 1. ICD 10 is not finished it has just begun 2. Continue to refine your ICD 10 strategy 3. What percentage of specified codes is your
More informationIcd 10 code lung cancer with mets to bone These procedure codes will be included in the next Nurse Practitioner Provider Manual Update.
Icd 10 code lung cancer with mets to bone These procedure codes will be included in the next Nurse Practitioner Provider Manual Update. SCC is ONLY available to pregnant females, women up to six months
More informationDermatology Procedure Coding
Dermatology Procedure Coding Anatomy Two layers that make up human skin Epidermis most superficial layer Composed of four to five layers called stratum Anyone remember the mnemonic? Thickness varies based
More information